Setback For Roche As Delhi Court Dismisses Patent Claims On Tarceva; Cipla Allowed To Market Copies
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - A sensational fight that lasted more than a year between Roche and India's Cipla over the patentability of anti-cancer drug Tarceva (erlotinib) ended in a defeat for the Swiss drug maker as the Delhi High Court in a landmark decision dismissed its patent claims